Copyright 2015 American Medical Association. All rights reserved.
Drafting of the manuscript: Kirkcaldy.
Critical revision of the manuscript for important intellectual content: Hook, Soge,
del Rio, Kubin, Zenilman, Papp.
Statistical analysis: Kirkcaldy.
Obtained funding: Soge, del Rio.
Administrative, technical, or material support: Kirkcaldy, Hook, Soge, Kubin,
Zenilman, Papp.
Study supervision: Kirkcaldy, Zenilman.
Conflict of Interest Disclosures: The authors have completed and submitted
the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Hook
reported receiving grants from Becton Dickinson, Hologic, Roche Molecular,
and Cempra; serving as a consultant for Rib-X (Melinta) and Cempra;
receiving honoraria from Becton Dickinson, Roche Molecular, and Cepheid;
and receiving royalties from McGraw-Hill. No other disclosures
were reported.
Funding/Support: The Gonococcal Isolate Surveillance Project is funded by the
CDC, an agency of the US Department of Health and Human Services.
Role of the Funder/Sponsor: Staff from the CDC had a role in the design and
conduct of the study; collection, management, analysis, and interpretation of
data; preparation, review, or approval of the manuscript; and decision to submit
the manuscript for publication.
Disclaimer: The findings and conclusions in this report are those of the authors
and do not necessarily represent the official position of the CDC.
1. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually
transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer
a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly
Rep. 2012;61(31):590-594.
2. Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance
Project (GISP) protocol. http://www.cdc.gov/std/gisp/gisp-protocol-oct-2014
.pdf. Accessed January 14, 2015.
3. Ison CA, Town K, Obi C, et al; GRASP Collaborative Group. Decreased
susceptibility to cephalosporins among gonococci: data from the Gonococcal
Resistance to Antimicrobials Surveillance Programme (GRASP) in England and
Wales, 2007-2011. Lancet Infect Dis. 2013;13(9):762-768.
4. European Centre for Disease Prevention and Control. Gonococcal
antimicrobial susceptibility in Europe 2012. http://ecdc.europa.eu/en
/publications/Publications/gonococcal-antimicrobial-susceptibility
-surveillance-Europe-2012.pdf. Accessed May 8, 2015.
5. Kidd S, Lee MV, Maningas E, et al. Gonococcal susceptibility to
cephalosporins--Hawaii, 2003 to 2011. Sex Transm Dis. 2013;40(9):756-759.
Flavored Tobacco Product Use Among US Youth
Aged 12-17 Years, 2013-2014
Most tobacco use begins during youth and young adulthood.1
Recent declines in prevalence of cigarette smoking among
youth have coincided with increased use of e-cigarettes and
hookahs.2 Although flavors
other than menthol are pro-
hibited in cigarettes in the
United States,3 flavored non-
cigarettetobaccoproductsare
widely available and may appeal to youth. We examined fla-
vored tobacco use among a nationally representative sample
of US youth.
Methods | The Population Assessment of Tobacco and Health
(PATH) Study is a household-based, nationally representa-
tive, longitudinal cohort study of 45 971 adults and
youth (12-17 years) in the United States. We analyzed youth
data from wave 1, collected September 2013 through
December 2014 (the survey is available in the eAppendix
in the Supplement). Among youth within participating
households (weighted household screener rate, 54%), 78.4%
participated in an audio computer-assisted interview.
Nonresponse analysis showed few differences with re-
ferent national surveys.4 Survey weights were adjusted for
nonresponse.
Parents and emancipated youth provided written in-
formed consent, whereas youth assented to participate. Fur-
ther details regarding the study methods are available.4 The
study was conducted by Westat and approved by the Westat
institutional review board.
Youth responded to questions about ever and past
30-day use of tobacco products including cigarettes,
e-cigarettes, hookahs, cigars (traditional cigars, cigarillos, fil-
tered cigars), pipe tobacco, all types of smokeless tobacco,
dissolvable tobacco, bidis, and kreteks. For each product ever
used, youth endorsed whether the first product they used
was flavored (eg, "Was the first e-cigarette you used flavored
to taste like menthol, mint, clove, spice, candy, fruit, choco-
late, alcohol [such as wine or cognac], or other sweets?").
Users of noncigarette products reported any past 30-day use
of a flavored product. Past 30-day noncigarette tobacco users
also reported reasons for product use, including "(It) comes
in flavors I like," for each product. Past 30-day cigarette
smokers reported smoking cigarettes flavored to taste like
menthol or mint.
We used SAS version 9.3 (SAS Institute Inc) survey pro-
cedures to account for weighting and calculated proportions
with 95% confidence intervals for all measures. Estimates
from denominators of fewer than 50 users are suppressed;
estimates with relative standard errors greater than 30%
are flagged.
Results | Of the 13 651 youth enrolled and included in this
analysis, 51.3% were male, 54.5% non-Hispanic white, 13.7%
non-Hispanic black, and 22.5% Hispanic. Mean respondent
age was 14.5 (SD, 0.02) years. Table 1 summarizes ever and
past 30-day use of flavored tobacco products. The majority of
youth ever-users reported that the first product they had
used was flavored, including 88.7% of ever hookah users,
81.0% of ever e-cigarette users, 65.4% of ever users of any
cigar type, and 50.1% of ever cigarette smokers. For past
30-day youth tobacco use, the overall proportion of flavored
product use was 79.8% (95% CI, 77.3%-82.3%) among users
of any product and 89.0% among hookah users, 85.3%
among e-cigarette users, 71.7% among users of any cigar
type, and 59.5% among cigarette smokers.
Table 2 presents leading reasons for use among past
30-day noncigarette tobacco users. Youth consistently
reported product flavoring as a reason for use across all
product types, including e-cigarettes (81.5%), hookahs
(78.9%), cigars (73.8%), smokeless tobacco (69.3%), and
snus pouches (67.2%).
Discussion | Among a survey of youth aged 12 to 17 years, the
majority who self-reported ever experimenting with tobacco
started with a flavored product, and most current youth
tobacco users reported use of flavored products. This study
extends a recent national report5 on youth use of flavored
tobacco products by examining first use of flavored product
among ever users by products and flavorings as a reason for
Supplemental content at
jama.com
Letters
jama.com (Reprinted) JAMA November 3, 2015 Volume 314, Number 17 1871
Copyright 2015 American Medical Association. All rights reserved.
Downloaded From: http://jama.jamanetwork.com/ by a Labtiva Inc. User on 11/05/2015
Copyright 2015 American Medical Association. All rights reserved.
noncigarette tobacco use. Consistent with national school-
based estimates,5 this study confirms widespread appeal of
flavored products among youth tobacco users. In addition to
continued proven tobacco control and prevention strategies,
efforts to decrease use of flavored tobacco products among
youth should be considered.1
Study limitations include potential difficulty with recall
because youth often experiment with many products. This
cross-sectional analysis does not allow direct estimation of
flavoring's role in initiation of tobacco use among youth. In
addition, there are mode differences in household- vs school-
based youth tobacco surveys.6 Data from future PATH Study
waves can provide information on tobacco use trajectories
following experimentation with flavored compared with
nonflavored products.
Bridget K. Ambrose, PhD, MPH
Hannah R. Day, PhD
Brian Rostron, PhD
Kevin P. Conway, PhD
Nicolette Borek, PhD
Andrew Hyland, PhD
Andrea C. Villanti, PhD, MPH
Author Affiliations: CenterforTobaccoProducts,USFoodandDrug
Administration,SilverSpring,Maryland(Ambrose,Day,Rostron,Borek); Division of
Epidemiology, Services, and Prevention Research, National Institute on Drug
Abuse, Bethesda, Maryland (Conway); Department of Health Behavior, Roswell
ParkCancerInstitute,Buffalo,NewYork(Hyland);SchroederInstituteforTobacco
Research and Policy Studies at Truth Initiative, Washington, DC (Villanti).
Corresponding Author: Bridget K. Ambrose, PhD, MPH, Office of Science,
Center for Tobacco Products, US Food and Drug Administration,
10903 New Hampshire Ave, Bldg 75, Room 4432, Silver Spring, MD, 20993
(bridget.ambrose@fda.hhs.gov).
Published Online: October 26, 2015. doi:10.1001/jama.2015.13802.
Author Contributions: Drs Ambrose and Day had full access to all of the data in
the study and take responsibility for the integrity of the data and the accuracy
of the data analysis.
Study concept and design: Ambrose, Conway, Borek, Hyland, Villanti.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Ambrose.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Day, Rostron.
Administrative, technical or material support: Ambrose, Borek, Villanti.
Study supervision: Conway, Borek, Hyland.
Conflict of Interest Disclosures: The authors have completed and submitted
the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were
reported.
Funding/Support: Funded by the National Institute on Drug Abuse (NIDA),
National Institutes of Health, and the US Food and Drug Administration (FDA),
Department of Health and Human Services, under contract
HHSN271201100027C.
Table 1. Prevalence of Ever and Past 30-Day Use of Tobacco Products, Proportion of Ever Users Reporting That the First Product Used Was Flavored,
and Proportion of Past 30-Day Users Reporting Use of a Flavored Product, by Product--Population Assessment of Tobacco and Health Study Youth
Respondents Aged 12-17 Years, 2013-2014
Tobacco
Product
Ever Product Use Past 30-d Tobacco Product Use
Prevalence of Ever Product Usea,b
Proportion of Ever Users Reporting
First Product Used Was Flavoreda,c
Prevalence of Past 30-d
Product Usea,d
Proportion of Flavored Use Among
Past 30-d Youth Tobacco Usersa,e
Unweighted,
No.
Weighted, %
(95% CI)
Unweighted,
No.
Weighted, %
(95% CI)
Unweighted,
No.
Weighted, %
(95% CI)
Unweighted,
No.
Weighted, %
(95% CI)
Any
tobaccof
2900 21.4 (20.4-22.4) 2256 80.8 (79.1-82.5) 1152 8.5 (7.9-9.1) 919 79.8 (77.3-82.3)
Cigarettes 1838 13.4 (12.6-14.2) 902 50.1 (47.1-53.1) 634 4.6 (4.2-5.0) 383 59.5 (55.1-64.0)
e-Cigarettes 1452 10.7 (10.0-11.3) 1154 81.0 (78.5-83.5) 418 3.1 (2.7-3.5) 354 85.3 (81.2-89.5)
Any cigarsg 1048 7.6 (7.1-8.2) 652 65.4 (62.4-68.3) 340 2.5 (2.2-2.7) 245 71.7 (65.9-77.4)
Hookahs 1006 7.4 (6.8-8.1) 877 88.7 (86.6-90.7) 226 1.7 (1.3-2.0) 198 89.0 (84.8-93.1)
Smokeless
tobacco
(excluding
snus)
574 4.4 (3.9-4.8) 391 68.9 (64.7-73.1) 180 1.4 (1.2-1.7) 146 81.0 (75.7-86.2)
Snus
pouches
227 1.7 (1.4-2.0) 184 81.2 (75.9-86.4) 64 0.5 (0.4-0.6) 54 80.4 (70.5-90.4)
Pipes 259 1.9 (1.6-2.1) 77 29.4 (23.2-35.6) 41 0.3 (0.2-0.4)h 14 NAh
Abbreviation: NA, not available (suppressed).
a Individuals whose response was missing or who responded "don't know" were
excluded from the denominator.
b Defined as ever having used the product, even 1 to 2 puffs or times. Excluded
from denominator: n = 141 for any tobacco, n = 20 for cigarettes; n = 21 for
e-cigarettes, n = 5 for any cigars, n = 9 for hookahs, n = 120 for smokeless
tobacco, n = 120 for snus pouches, and n = 6 for pipes.
c Excluded from denominator: n = 107 ever any tobacco users, n = 53 ever
cigarette smokers, n = 22 ever e-cigarette users, n = 54 ever any cigar users,
n = 14 ever hookah users, n = 9 ever smokeless tobacco users, n = 2 ever snus
pouch users, and n = 7 ever pipe tobacco smokers.
d Excluded from denominator: n = 74 for any tobacco, n = 18 for cigarettes,
n = 30 for e-cigarettes, n = 9 for cigars, n = 7 for hookahs, n = 13 for smokeless
tobacco products, n = 2 for snus pouches, and n = 10 for pipes.
e Excluded from denominator: n = 1 for cigarettes and n = 1 for cigars.
f Represents combination of cigarette, e-cigarette, any cigar, hookah, smokeless
tobacco, snus pouch, pipe, bidi, kretek, and dissolvable tobacco product use.
Estimates of ever and current use of bidis, kreteks, and dissolvable tobacco
products are not presented owing to small sample sizes of product users.
g Respondents who indicated ever having used a cigar were asked about use of
traditional cigars, cigarillos, and filtered cigars separately. Respondents
indicating use of 2 or more types of cigars (traditional, cigarillo, filtered cigars)
were asked about the flavor status of each type of cigar separately. Any
respondent who reported ever using 2 or more types of cigars had their
responses aggregated, so that if any of the first traditional, cigarillo, or filtered
cigars they used were flavored, they were included in the estimate of ever
cigar users reporting that their first cigar was flavored. Likewise, respondents
who reported using 2 or more types of cigars in the past 30 days and reported
past 30-day flavored use of any cigar were included in the estimate of flavored
cigar use among past 30-day cigar users.
h Past 30-day use estimates for pipes are flagged because of unstable estimates
(relative standard error >30%); proportion of flavored product use among
past 30-day pipe users are suppressed because of small denominators (<50).
Letters
1872 JAMA November 3, 2015 Volume 314, Number 17 (Reprinted) jama.com
Copyright 2015 American Medical Association. All rights reserved.
Downloaded From: http://jama.jamanetwork.com/ by a Labtiva Inc. User on 11/05/2015
Copyright 2015 American Medical Association. All rights reserved.
Role of the Funders/Sponsors: Staff from the NIDA and the FDA contributed
to the design and conduct of the study; management, analysis, and
interpretation of the data; preparation, review, and approval of the manuscript;
and the decision to submit the manuscript for publication. The NIDA and the
FDA were not directly involved in the collection of study data.
Disclaimer: The views and opinions expressed in this article are those of the
authors and do not necessarily represent the views, official policy, or position of
the US Department of Health and Human Services or any of its affiliated
institutions or agencies.
Additional Contributions: We thank David Maklan, PhD, and Charles Carusi,
PhD, from Westat Inc for contributions to study design and supervision, as well
as data acquisition. We also thank Kristie Taylor, PhD, from Westat Inc for
contributions to the study design and analytic support. Drs Maklan, Carusi, and
Taylor received compensation for their contributions to the PATH Study.
1. US Department of Health and Human Services. Preventing Tobacco Use
Among Youth and Young Adults: A Report of the Surgeon General. Atlanta, GA:
US Dept of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and Health Promotion,
Office on Smoking and Health; 2012.
2. Arrazola RA, Singh T, Corey CG, et al; Centers for Disease Control
and Prevention (CDC). Tobacco use among middle and high school
students--United States, 2011-2014. MMWR Morb Mortal Wkly Rep. 2015;64
(14):381-385.
3. Family Smoking Prevention and Tobacco Control Act, Pub L No. 111-31, 123
Stat 1776 (2009).
4. US Office of Management and Budget. PATH Study Interim Report.
http://www.reginfo.gov/public/do/PRAViewDocument?ref_nbr=201506-0925
-002. Accessed October 7, 2015.
5. Corey CG, Ambrose BK, Apelberg BJ, King BA. Flavored tobacco product use
among middle and high school students--United States, 2014. MMWR Morb
Mortal Wkly Rep. 2015;64(38):1066-1070.
6. Biglan M, Gilpin EA, Rohrbach LA, Pierce JP. Is there a simple correction
factor for comparing adolescent tobacco-use estimates from school- and
home-based surveys? Nicotine Tob Res. 2004;6(3):427-437.
COMMENT & RESPONSE
Use of Implantable Cardioverter-Defibrillators
Among Medicare Patients
To the Editor Dr Pokorney and colleagues1 described low (8.1%)
use of implantable cardioverter-defibrillators (ICDs) in older
patients with myocardial infarction (MI) who met criteria for
implantation. They inferred that many older patients with MI
notreferredforICDsmighthavebenefitedwithsignificantpro-
longation of life. They also suggested that modifiable system
factors contribute to ICD underuse.
The authors' perspectives contrast with those of
Santangeli et al,2 who completed a meta-analysis of ran-
domized trials of ICDs for the primary prevention of sudden
cardiac death. That report showed ICD benefits declined
with age and were no longer statistically significant after
age 65 years. Although the mechanisms for the decreasing
Table 2. Leading Reasons for Noncigarette Tobacco Product Use Among Past 30-Day Tobacco Users, by Product--Population Assessment of Tobacco
and Health Study Youth Respondents Aged 12-17 Years, 2013-2014a,b
Reasons for Use
% (95% CI)
e-Cigarettes
(n = 418)c
Any Cigars
(n = 340)c,d
Hookahs
(n = 226)c
Smokeless Tobacco
(n = 180)c
Snus Pouches
(n = 64)c
I use [product] because they come in flavors
I like
81.5 (77.9-85.0) 73.8 (68.2-79.4) 78.9 (73.4-84.3) 69.3 (62.6-76.0) 67.2 (55.7-78.6)
I use [product] because they are affordable 47.8 (42.9-52.6) 58.2 (52.7-63.6) 43.7 (36.5-51.0) 60.6 (52.6-68.6) 45.5 (32.1-58.8)
I use [product] because I can smoke/use them
at times when or in places where smoking
cigarettes isn't allowed
58.9 (54.1-63.7) 10.9 (7.1-14.8) 30.8 (24.1-37.5) 69.7 (63.3-76.0) 70.7 (58.7-82.7)
I use [product] because I like socializing while
using them
40.3 (34.9-45.8) 57.0 (51.7-62.4) 79.6 (74.6-84.5) NA NA
I use [product] because it doesn't bother
nonÂ­tobacco users
53.9 (48.1-59.8) NA NA 47.7 (40.4-55.0) 50.4 (39.7-61.2)
I use [product] because they might be less
harmful to me than cigarettes
79.1 (75.2-83.0) 29.9 (25.3-34.5) 60.6 (53.9-67.3) 51.4 (44.3-58.4) 36.9 (24.3-49.6)
I use [product] because they might be less
harmful to people around me than cigarettes
78.1 (74.3-81.8) NA NA 68.3 (62.1-74.6) 51.4 (38.7-64.2)
I use [product] because they don't smell 58.7 (54.2-63.2) NA NA 33.3 (27.4-39.1) 34.2 (22.1-46.4)
I use [product] because they help people
to quit smoking cigarettes
59.5 (54.6-64.5) 9.9 (6.6-13.2) 24.2 (18.1-30.2) 26.8 (21.2-32.5) 25.1 (15.1-35.1)
I use [product] because people who are
important to me use them
34.9 (30.6-39.2) 28.4 (23.5-33.2) 35.9 (30.3-41.6) 40.7 (32.9-48.6) 28.8 (17.8-39.7)
I use [product] because people in the media
or other public figures use them
36.1 (31.5-40.7) 30.7 (26.1-35.4) 28.8 (22.7-35.0) 27.4 (20.8-34.1) 23.8 (13.2-34.5)
Abbreviation: NA, not asked.
a Past 30-day noncigarette tobacco users were asked to indicate (yes/no)
whether particular reasons applied to their use of each specific product. A set
of 14 items were asked of e-cigarette, smokeless tobacco, snus pouch, and
dissolvable tobacco users; 10 were asked of cigar and hookah smokers; and a
set of 9 were asked of pipe smokers and users of bidis and kreteks. Items can
be accessed on the PATH Youth Baseline Questionnaire available in the
eAppendix in the Supplement.
b Individuals whose response was missing or responded "don't know" to
whether they used products in the past 30 days were excluded from the
denominator, including n = 30 for e-cigarettes, n = 9 for cigars, n = 7 for
hookahs, n = 13 for smokeless tobacco, and n = 2 for snus pouches. Estimates
for pipe, dissolvable tobacco, bidi, and kretek users are not presented owing
to small denominators of past 30-day users (n <50). Cited sample sizes reflect
unweighted Ns.
c Past 30-day users whose response was missing or who responded
"don't know" to any item regarding reasons for use were excluded from the
denominator (range of missing for each item, by product: n = 0-5 for cigars,
n = 0-4 for e-cigarettes and hookahs, n = 0-3 for smokeless tobacco,
and n = 0-1 for snus pouches).
d Questions regarding reasons for use were asked separately for past 30-day
use of traditional cigar, cigarillo, and filtered cigar. Any respondents reporting
past 30-day use of 2 or more types of cigars were asked to report on reasons
for use for each type of cigar separately. Responses were aggregated so that if
the reason was endorsed for any of the types of cigars, it was counted overall
as a positive response.
Letters
jama.com (Reprinted) JAMA November 3, 2015 Volume 314, Number 17 1873
Copyright 2015 American Medical Association. All rights reserved.
Downloaded From: http://jama.jamanetwork.com/ by a Labtiva Inc. User on 11/05/2015
